Sales 2024 * | 72.54M 6.05B | Sales 2025 * | 68.35M 5.7B | Capitalization | 242M 20.22B |
---|---|---|---|---|---|
Net income 2024 * | -168M -14.01B | Net income 2025 * | -167M -13.93B | EV / Sales 2024 * | 1.76 x |
Net cash position 2024 * | 115M 9.57B | Net cash position 2025 * | 281M 23.48B | EV / Sales 2025 * | -0.57 x |
P/E ratio 2024 * |
-1.56
x | P/E ratio 2025 * |
-1.97
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.18% |
Latest transcript on Nektar Therapeutics
Managers | Title | Age | Since |
---|---|---|---|
Howard Robin
CEO | Chief Executive Officer | 71 | 01/07/01 |
Robert Chess
CHM | Chairman | 66 | 01/91/01 |
Sandra Gardiner
DFI | Director of Finance/CFO | 58 | 17/23/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
R. Scott Greer
BRD | Director/Board Member | 65 | 01/10/01 |
Roy A. Whitfield
BRD | Director/Board Member | 70 | 01/00/01 |
Robert Chess
CHM | Chairman | 66 | 01/91/01 |
1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |